DC Circ. Urged To Overturn Endo-Impax Opioid Deal Win

By Kelly Lienhard · December 22, 2022, 5:49 PM EST

The Federal Trade Commission urged the D.C. Circuit to overturn a lower court's decision that allowed two pharmaceutical companies to continue an alleged pay-for-delay agreement, arguing that the companies are still...

To view the full article, register now.

Try a seven day FREE Trial

Already a subscriber? Click here to login

Documents

Brief

Case Information

Case Title

FTC v. Endo Pharmaceuticals Inc., et al

Case Number

Court

Appellate - DC Circuit

Nature of Suit

1410 Antitrust

Date Filed

May 24, 2022

Recent Articles By Kelly

February 13, 2024
Mallinckrodt Guts IP Suit Amid Oxide Rival's New Drug App
January 30, 2024
Allergan Asks 9th Circ. To Ignore Atty's Claims Of Fraud
January 29, 2024
McCarter & English Urges Against Updating Malpractice Suit
January 05, 2024
Sarepta Avoids IP Claims As Judge Finds UPenn Patent Invalid
January 03, 2024
Judge Pauses Apple Patent Suit Ahead Of PTAB Decision
December 11, 2023
Chamber Finds Drug Price Measures Will Stifle Research
December 08, 2023
New Drug Patent Proposal Sparks Worry Over Gov't Overstep
December 07, 2023
Biden Admin Looks To Take Over Expensive Drug Patents
December 01, 2023
Med Tech Co. Sues AI Maker Over Use Of 'Judi' Mark
November 17, 2023
Calif. Prosthetics Co. Says Sales Manager Stole Trade Secrets